Table 2 Early pregnancy endogenous hormones and breast cancer risk: Northern Sweden Maternity Cohort

 All women

Cases/controls

68/137

70/134

82/133

OR (95% CI)

Reference

1.06 (0.69–1.63)

1.29 (0.80–2.07)

0.15

 ER+/PR+

Cases/controls

47/98

54/94

51/90

OR (95% CI)

Reference

1.16 (0.69–1.93)

1.11 (0.62–1.97)

0.60

 All women

Cases/controls

67/127

78/126

65/121

OR (95% CI)

Reference

1.14 (0.74–1.75)

0.95 (0.59–1.54)

0.86

 ER+/PR+

Cases/controls

48/90

54/83

41/85

OR (95% CI)

Reference

1.13 (0.68–1.90)

0.81 (0.45–1.44)

0.72

 All women

Cases/controls

63/138

81/137

78/135

OR (95% CI)

Reference

1.27 (0.85–1.91)

1.25 (0.79–1.97)

0.45

 ER+/PR+

Cases/controls

47/97

60/96

47/93

OR (95% CI)

Reference

1.25 (0.77–2.02)

0.96 (0.55–1.65)

0.79

 All women

Cases/controls

30/137

77/136

84/134

OR (95% CI)

Reference

1.29 (0.84–1.96)

1.46 (0.96–2.21)

0.04

 ER+/PR+

Cases/controls

36/99

57/95

60/89

OR (95% CI)

Reference

1.69 (1.00–2.86)

1.94 (1.16–3.25)

0.01

 All women

Cases/controls

73/128

57/127

81/122

OR (95% CI)

Reference

0.81 (0.52–1.25)

1.16 (0.73–1.83)

0.47

 ER+/PR+

Cases/controls

44/97

41/79

59/84

OR (95% CI)

Reference

1.23 (0.72–2.12)

1.68 (0.96–2.94)

0.04

 All women

Cases/controls

74/138

80/134

67/134

OR (95% CI)

Reference

1.10 (0.72–1.68)

0.89 (0.56–1.40)

0.77

 ER+/PR+

Cases/controls

55/84

55/99

43/99

OR (95% CI)

Reference

0.75 (0.44–1.27)

0.55 (0.31–0.99)

0.05

 All women

Cases/controls

59/128

67/127

86/129

OR (95% CI)

Reference

1.21 (0.78–1.87)

1.68 (1.05–2.70)

0.13

 ER+/PR+

Cases/controls

44/85

46/83

55/96

OR (95% CI)

Reference

1.08 (0.64–1.83)

1.18 (0.67–2.08)

0.70